My IDSA Contact Us
IDSA NewsPrint-Friendly Newsletter
Forward to a Friend
Search Back Issues
 
Education & Training Resources Practice Guidelines Journals & Publications Policy & Advocacy Meetings About IDSA
November 2017
POLICY AND ADVOCACY
IDSA Continues to Press for Diagnostics Reimbursement

IDSA continues to advocate for appropriate reimbursement for ID diagnostic tests to ensure patient access to testing and to spur diagnostics innovation. IDSA successfully defeated recent proposals to curtail reimbursement for important ID diagnostics, and is now working to alter another harmful proposal.

IDSA Defeats CMS “Palmetto” Proposal to Reduce Diagnostics Reimbursement

The Centers for Medicare and Medicaid Services (CMS) last spring issued two draft Local Coverage Determination (dLCD) payment policies for Palmetto GBA’s multiplex nucleic acid tests for respiratory viruses and foodborne gastrointestinal (GI) panels that would severely curtail coverage and reimbursement for both tests. Palmetto GBA is a Medicare contractor that oversees Medicare payments in 45 states. IDSA worked with the Association for Molecular Pathology, the College of American Pathologists, the American Society for Microbiology, and the Pan-American Society for Clinical Virology to submit respiratory virus and GI comment letters on the proposed policies to provide expert clinical perspectives on how these panels are reasonable and necessary for patient care. In response to these efforts, Palmetto retracted both proposals.

IDSA Works to Prevent Proposed 10 Percent Reduction in Diagnostic Reimbursement

Over the past two years, CMS, at the direction of Congress, has attempted to collect data on private payor reimbursement for diagnostic tests on which to base revised Medicare reimbursement. IDSA and other physician organizations have repeatedly expressed concerns that that the data collection would be overly burdensome for clinical laboratories and subsequently result in inadequate reimbursement rates for diagnostic tests. CMS released preliminary diagnostics reimbursement rates in late September for diagnostic tests for 2018. The agency is planning to finalize the proposed rates in November, which are then scheduled to take effect on January 1, 2018. If the preliminary rates are implemented as planned, most ID diagnostic tests will get a 10 percent reduction in 2018, with a possibility of additional 10 percent reductions over the next two years for a total 30 percent reduction by 2020. These rates will not reflect market-based payments, as IDSA believes Congress intended.

IDSA submitted comments to CMS following the release of the preliminary 2018 rates outlining specific concerns and providing recommendations. The Society has also been working with the American Medical Association and a number of laboratorian- and clinician-focused organizations to educate Congress on the potential impacts of decreased reimbursement on patient care. The group met with House Committee on Energy and Commerce and Senate Finance Committee staff this summer to recommend in part that CMS issue an interim final rule so that the agency may conduct a regional survey of private payer payments for clinical tests.

IDSA will continue to advocate for a reimbursement system that promotes innovative diagnostics and improves patient access as CMS moves forward in their efforts to reform clinical laboratory diagnostic reimbursement. Join the Member Advocacy Program (MAP) today to stay abreast of IDSA advocacy efforts and how you can get involved.

< Previous Article | Next Article >

Post a comment

Your name:

Your comment:


PATIENT CARE AND SCIENCE
HIVMA Releases Guideline on HIV and Chronic Pain
ACIP Makes New Recommendations on Shingles, Mumps Vaccines
Weighing in on HHS Report on Vaccine Innovation
Updates on NIHís Next Generation Researchers Initiative
CLINICAL PRACTICE MANAGEMENT
IDSA to UHC: Donít Deny Payment for Cognitive Services
Reimbursement for Telemedicine Could Get Easier
How to Stay Abreast of CMSís Quality Payment Program
POLICY AND ADVOCACY
IDSA Remains Committed to Fighting Antimicrobial Resistance
FY2018 Funding News
IDSA Continues to Press for Diagnostics Reimbursement
FDA Public Workshop on Antimicrobial Susceptibility Tests
IDSA Member Testifies at New York State Hearing on Lyme Disease
GLOBAL HEALTH
Science Speaks Covers IDWeek, Union World Conference on Lung Health
Congressional Study Tour to CDC Global Health
EDUCATION AND RESOURCES
Fellowship in Stewardship and Resistance Receives CDC Funding
HIVMA Clinical Fellowship and Medical Students Program
PCORI Funding Announcement: Community-Acquired Pneumonia
FROM THE PRESIDENT
Maintaining Our Momentum
TOP STORIES
IDSA Launches Antimicrobial Stewardship Centers of Excellence Program
Updated Guideline on Infectious Diarrhea Now Available
IDWeek 2017 Recap
Journal Club
IDSA | 1300 Wilson Blvd., Suite 300 | Arlington, VA 22209 | Phone: (703) 299-0200
To ensure delivery, please add 'info@idsociety.org' to your email address book or Safe Sender List.
If you are still having problems receiving our communications,
see our white-listing page for more details.